Ocrevus Zunovo 23000 U/23mL
ocrelizumab and hyaluronidase · INJECTION, SOLUTION · Genentech, Inc.
Ocrevus Zunovo is a injection, solution containing ocrelizumab and hyaluronidase at 23000 U/23mL, taken subcutaneous. Manufactured by Genentech, Inc..
Key Facts
- Brand Name
- Ocrevus Zunovo
- Generic Name
- ocrelizumab and hyaluronidase
- NDC Code (Product)
50242-554- Manufacturer
- Genentech, Inc.
- Strength
- 23000 U/23mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761371
- Drug Class
- Endoglycosidase [EPC]; CD20-directed Cytolytic Antibody [EPC]
- Marketing Start
- 09/13/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is Ocrevus Zunovo used for?
Ocrevus Zunovo contains ocrelizumab and hyaluronidase. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Ocrevus Zunovo a controlled substance?
Ocrevus Zunovo is not classified as a controlled substance by the DEA.
What is the generic name for Ocrevus Zunovo?
The generic name for Ocrevus Zunovo is ocrelizumab and hyaluronidase. There are no other listed brand versions of ocrelizumab and hyaluronidase.
What is the NDC code for Ocrevus Zunovo 23000 U/23mL?
The NDC (National Drug Code) for Ocrevus Zunovo 23000 U/23mL is 50242-554, listed by Genentech, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)